Intranasal AAV Delivery Bypassing Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for mucopolysaccharidoses, such as allogeneic hematopoietic stem cell transplantation and enzyme replacement therapy, are ineffective in addressing neurological manifestations due to the inability of enzymes to penetrate the blood-brain barrier, leading to persistent neurological deficits and high treatment costs.
Innovation Solution
Intranasal administration of recombinant adeno-associated virus (rAAV) vectors expressing lysosomal storage enzymes, which bypass the blood-brain barrier by traveling directly from the nasal mucosa to the brain along olfactory and trigeminal neural pathways, providing effective enzyme replacement therapy for neurological symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic hematopoietic stem cell transplantation is performed, then peripheral conditions improve and some neurological benefit is achieved, but the treatment is highly invasive, expensive, and does not fully address neurological manifestations
Solution Approach 1:
The treatment is divided into two separate components: (1) allogeneic HSCT to address peripheral manifestations through metabolic cross-correction, and (2) intranasal enzyme delivery to specifically target the CNS. This segmentation allows each component to be optimized for its specific function without the compromises of a single comprehensive treatment.
Solution Approach 2:
The patent introduces an intermediary delivery system (intranasal administration of enzyme or enzyme-encoding vectors) that bridges the gap between peripheral treatment and CNS delivery. This intermediary approach avoids the need for direct invasive CNS intervention while still achieving therapeutic enzyme levels in the brain.
2Reliability
If enzyme replacement therapy is administered peripherally, then storage materials are cleared in peripheral organs, but the enzyme cannot penetrate the blood-brain barrier to treat neurological symptoms
Solution Approach 1:
The patent transitions from the conventional route of enzyme delivery (systemic/peripheral administration) to an alternative dimension of delivery (intranasal route). This dimensional change in administration route allows the enzyme to bypass the blood-brain barrier through direct nasal-to-brain transport via olfactory and trigeminal neural pathways.
Solution Approach 2:
Instead of attempting to modify the enzyme itself to cross the BBB, the patent uses a copy approach by delivering the enzyme-encoding genetic material (AAV vectors) directly to the CNS. The host cells then produce the enzyme locally, creating a self-sustaining source of therapeutic enzyme within the brain without requiring the enzyme to cross the BBB from peripheral circulation.
3Ease of operation
If invasive intrathecal enzyme administration is performed, then enzyme can reach the CNS, but the treatment requires repeated infusions and has high cost
Solution Approach 1:
The patent performs preliminary action by delivering enzyme-encoding genetic material (AAV vectors) directly to the CNS through intranasal administration. This establishes a permanent or long-lasting source of enzyme production within the brain, eliminating the need for repeated infusions required by traditional ERT approaches.
Solution Approach 2:
The patent implements self-service by enabling the CNS to produce its own therapeutic enzyme through delivery of enzyme-encoding genetic material. The host cells take over the production of the missing enzyme, creating a self-sustaining therapeutic system that does not require continuous external administration.
4Ease of operation
If peripherally administered enzyme is used, then treatment is less invasive, but the enzyme fails to reach the CNS to prevent neurological deterioration
Solution Approach 1:
The patent maintains the advantage of non-invasive intranasal administration while overcoming the limitation of poor CNS penetration by changing the dimension of enzyme delivery from peripheral circulation to direct nasal-to-brain transport. This allows the enzyme to reach the CNS through alternative pathways (olfactory and trigeminal neural pathways) that bypass the blood-brain barrier.
Solution Approach 2:
The patent uses the nasal mucosa and neural pathways as an intermediary route to deliver enzyme or enzyme-encoding material to the CNS. This intermediary pathway serves as a bridge between the non-invasive administration route and the CNS target, enabling therapeutic delivery without invasive procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves widespread enzyme activity in the brain, preventing or inhibiting neurological degeneration in mammals with mucopolysaccharidoses, offering a non-invasive, cost-effective, and potentially unlimited dosing regimen for treating neurological symptoms.
Implementation Method 1
bypass the blood-brain barrier by traveling directly from the nasal mucosa to the brain along olfactory and trigeminal neural pathways
Implementation Method 2
bypass the blood-brain barrier by traveling directly from the nasal mucosa to the brain along olfactory and trigeminal neural pathways
Implementation Method 3
widespread enzyme activity in the brain, preventing or inhibiting neurological degeneration in mammals with mucopolysaccharidoses
Data Source
AI summary
The invention provides a method to prevent, inhibit or treat one or more neurological symptoms associated with a lysosomal storage disease in a mammal in need thereof, which includes intranasally administering to the mammal a composition comprising an effective amount of a lysosomal storage enzyme or a recombinant adeno-associated virus vector comprising an open reading frame encoding a lysosomal storage enzyme. Also provided are compositions and devices useful in the methods.